Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ADVM |
---|---|---|
09:32 ET | 1134 | 8.07 |
09:36 ET | 100 | 8.075 |
09:38 ET | 200 | 8.09 |
09:39 ET | 1264 | 8.01 |
09:41 ET | 459 | 7.93 |
09:43 ET | 1154 | 7.9 |
09:48 ET | 500 | 7.85 |
09:52 ET | 100 | 7.86 |
09:57 ET | 1200 | 7.85 |
09:59 ET | 299 | 7.78 |
10:01 ET | 300 | 7.81 |
10:03 ET | 100 | 7.78 |
10:06 ET | 996 | 7.78 |
10:08 ET | 1778 | 7.89 |
10:12 ET | 116 | 7.865 |
10:14 ET | 700 | 7.81 |
10:24 ET | 100 | 7.81 |
10:30 ET | 100 | 7.83 |
10:32 ET | 400 | 7.83 |
10:33 ET | 831 | 7.87 |
10:37 ET | 200 | 7.83 |
10:39 ET | 5300 | 7.84 |
10:42 ET | 100 | 7.9 |
10:50 ET | 400 | 7.91 |
10:53 ET | 1000 | 7.9 |
10:57 ET | 100 | 7.89 |
11:06 ET | 400 | 7.84 |
11:08 ET | 735 | 7.81 |
11:09 ET | 560 | 7.81 |
11:11 ET | 300 | 7.8106 |
11:13 ET | 200 | 7.85 |
11:22 ET | 300 | 7.81 |
11:24 ET | 200 | 7.81 |
11:27 ET | 100 | 7.81 |
11:29 ET | 700 | 7.81 |
11:31 ET | 900 | 7.875 |
11:38 ET | 200 | 7.87 |
11:51 ET | 200 | 7.81 |
11:58 ET | 100 | 7.84 |
12:00 ET | 100 | 7.81 |
12:02 ET | 1820 | 7.8 |
12:07 ET | 2150 | 7.75 |
12:09 ET | 100 | 7.755 |
12:12 ET | 100 | 7.73 |
12:14 ET | 200 | 7.755 |
12:16 ET | 200 | 7.73 |
12:20 ET | 2624 | 7.815 |
12:23 ET | 200 | 7.81 |
12:25 ET | 100 | 7.81 |
12:32 ET | 100 | 7.765 |
12:34 ET | 300 | 7.75 |
12:39 ET | 100 | 7.785 |
12:45 ET | 200 | 7.76 |
12:48 ET | 100 | 7.73 |
12:54 ET | 100 | 7.775 |
12:57 ET | 100 | 7.76 |
12:59 ET | 100 | 7.75 |
01:03 ET | 100 | 7.745 |
01:06 ET | 200 | 7.71 |
01:10 ET | 100 | 7.7386 |
01:14 ET | 300 | 7.71 |
01:19 ET | 100 | 7.71 |
01:21 ET | 100 | 7.71 |
01:32 ET | 100 | 7.71 |
01:33 ET | 200 | 7.71 |
01:39 ET | 100 | 7.71 |
01:46 ET | 988 | 7.71 |
01:50 ET | 100 | 7.66 |
01:51 ET | 2287 | 7.7 |
01:55 ET | 100 | 7.66 |
02:08 ET | 100 | 7.66 |
02:09 ET | 1000 | 7.6604 |
02:13 ET | 1100 | 7.68 |
02:18 ET | 100 | 7.69 |
02:20 ET | 1100 | 7.6891 |
02:22 ET | 410 | 7.67 |
02:24 ET | 640 | 7.664 |
02:29 ET | 600 | 7.62 |
02:33 ET | 100 | 7.63 |
02:36 ET | 1601 | 7.65 |
02:38 ET | 100 | 7.65 |
02:45 ET | 100 | 7.625 |
02:47 ET | 108 | 7.61 |
02:49 ET | 204 | 7.61 |
02:51 ET | 650 | 7.63 |
02:54 ET | 560 | 7.6025 |
02:58 ET | 100 | 7.65 |
03:00 ET | 1600 | 7.665 |
03:02 ET | 100 | 7.665 |
03:12 ET | 150 | 7.6846 |
03:14 ET | 100 | 7.66 |
03:20 ET | 400 | 7.635 |
03:23 ET | 100 | 7.62 |
03:25 ET | 100 | 7.62 |
03:27 ET | 100 | 7.64 |
03:30 ET | 1201 | 7.67 |
03:32 ET | 100 | 7.675 |
03:36 ET | 104 | 7.68 |
03:41 ET | 100 | 7.67 |
03:43 ET | 2972 | 7.66 |
03:45 ET | 1201 | 7.715 |
03:48 ET | 1300 | 7.69 |
03:50 ET | 1200 | 7.73 |
03:52 ET | 200 | 7.72 |
03:54 ET | 1305 | 7.71 |
03:56 ET | 200 | 7.68 |
03:57 ET | 2123 | 7.64 |
03:59 ET | 2225 | 7.62 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Adverum Biotechnologies Inc | 158.2M | -0.7x | --- |
Rezolute Inc | 158.5M | -3.5x | --- |
Regulus Therapeutics Inc | 157.8M | -1.7x | --- |
Acumen Pharmaceuticals Inc | 158.6M | -2.5x | --- |
bluebird bio Inc | 182.7M | -1.3x | --- |
CervoMed Inc | 156.9M | 9.6x | --- |
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $158.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.08 |
EPS | $-10.23 |
Book Value | $8.23 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.